Triumvira Immunologics
PrivateLast Round
Series A
Extension
Mar 17, 2022
Total Funding Raised
$145M
Company Overview
Triumvira Immunologics is a biotechnology company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Triumvira Immunologics Comparables
Compare Triumvira Immunologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| WindMIL Therapeutics | 83% | |
| A2 Biotherapeutics | 81% | |
| Adaptimmune Therapeutics | 78% | |
Triumvira Immunologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Mar 17, 2022 | ||||
| Series A | Aug 27, 2020 |
Key People
Founding team and executive leadership
Triumvira Immunologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| B Capital Group | Series A, Series A Extension |
| Oceanpine Capital | Series A |
| Northpond Ventures | Series A |
| Bloom Burton & Co. | Series A, Series A Extension |
| Viva Biotech | Series A |
| Northpond Ventures | Series A Extension, Series A |
| ATEM Capital | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 13, 2025
Will present updated clinical data at the 2025 SITC Spring Scientific Conference.
- Jan 23, 2025
Presented abstract at the 2025 ASCO Gastrointestinal Cancers Symposium.
Triumvira Immunologics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Triumvira Immunologics's valuation, stock price, and market status.